logo image
search icon
Global Antisense Oligonucleotide Therapeutics Market

Antisense Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report, Analysis Report Type Of Antisense Molecule (RNA Molecule And DNA Molecule), ASO Generation, Phase Of Development Of Lead Candidates, Target Genes, Target Disease Indications, Target Therapeutic Areas, Route Of Administration and Type Of Therapy, By Region, Forecasts, 2024-2031

Report ID : 1245 | Published : 2024-06-15 | Pages: 180 | Format: PDF/EXCEL

The Antisense Oligonucleotide Therapeutics Market is predicted to grow at a 13.50 % CAGR during the forecast period for 2024-2031.

.oligonucleotide

Antisense oligonucleotide is crucial in present medicine because it inhibits the expression of disease-causing genes by acting on messenger RNA before the protein is produced. This is attributed to rising antisense drug acceptability, increased R&D funding, rising neurodegenerative disorders, and an ageing population. The antisense oligonucleotides market will benefit from a high number of regulatory approvals from the Food and Drug Administration (FDA), for the use of innovative antisense oligonucleotides medications. Furthermore, mergers and acquisitions to enhance their product offerings are expected to be a major driver for the worldwide antisense oligonucleotides market over the upcoming years.

However, the high cost of antisense oligonucleotide therapeutics and the availability of synthetic chemicals are factors projected to limit the overall growth of the antisense oligonucleotide therapeutics market over the coming years. In addition, developing a new set of unique regulatory requirements is a difficulty that is inhibiting the worldwide antisense oligonucleotide market's growth. Also, Investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Antisense Oligonucleotide Therapeutics market over the forecast period.

Competitive Landscape

Some major key players in the Antisense Oligonucleotide Therapeutics Market:

  • Sarepta Therapeutics,
  • Biogen,
  • Alnylam Pharmaceuticals, Inc
  • Antisense Therapeutics Limited,
  • Sarna Therapeutics GmbH,
  • Arrowhead Pharmaceuticals, Inc.,
  • Atlantic Pharmaceuticals, Inc.,
  • Enzo Pharmaceuticals, Inc.,
  • Bio-Path Holdings, Inc.,
  • Gene Signal International SA,
  • GlaxoSmithKline plc,
  • Gerona Corporation,
  • Gradualist,
  • ICO Therapeutics,
  • Aptos Biosciences,
  • Marina Biotech,
  • mirage Therapeutics, Inc.,
  • Synodic, Inc.,
  • Oncogene Pharmaceuticals Inc.,
  • Pharm axis Ltd,
  • Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc.,
  • RI Pharmaceuticals,
  • Ionis Pharmaceuticals
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Sterna Biologicals
  • Wave Life Sciences

Market Segmentation:

The Antisense Oligonucleotides Market is segmented type of antisense molecule, ASO generation, phase of development, lead candidates, target genes, target disease indications, target therapeutic areas, route of administration, type of therapy. Based on type of antisense molecule, the market is segmented into RNA molecule and DNA molecule. The market is segmented ASO generation into first-generation, second-generation, third-generation and next-generation. Based on phase of development the market is segmented commercial, clinical, preclinical, and discovery stage antisense oligonucleotides market report scope. Based on the route of administration, the market segmented into subcutaneous, intravenous, intrathecal, intravitreal and others. Based on the type of therapy, the market segmented into monotherapy, combination therapy and both.

Based on Therapy, the monotherapy segment is accounted as a major contributor in the Antisense Oligonucleotide Therapeutics market.

The Monotherapy category is expected to hold a major share in the global Antisense Oligonucleotide Therapeutics market in 2021. The market is expected to increase due to a rise in regulatory approvals of monotherapy medications. Furthermore, the increased prevalence of prostate cancer is expected to drive the market forward during the forecast period.

RNA Molecule segment witnessed growth at a rapid rate

The RNA Molecule segment is projected to grow at a rapid rate in the global Antisense Oligonucleotide Therapeutics market during the forecast period. Collaboration operations between pharmaceutical firms and Contract Research Organizations (CROs) focusing on drug delivery are projected to benefit the antisense & RNA molecule industry, particularly in nations such as the United States, Germany, the United Kingdom, China, and India. In addition, many other antisense technologies and oligonucleotide molecules are also being developed for non-neurodegenerative disorders.

In the region, the North America Antisense Oligonucleotide Therapeutics market holds a significant revenue share.

The North America Antisense Oligonucleotide Therapeutics market is expected to register the highest market share in terms of revenue soon. Several biotechnology companies have made significant expenditures on the development of RNAi therapeutics. Big pharmaceutical companies have gone into partnership or license arrangements with several smaller companies to profit from the predicted revenue increase in this industry over the projection period. Several medication candidates now undergoing clinical trials have shown promising results and are moving forward in the development process. If such studies continue to yield positive results, the North American market is likely to see a significant demand increase throughout the forecast period.

Europe is expected to be the dominant region in the global antisense oligonucleotides market over the forecast period. This is due to the region's rising approval of novel antisense oligonucleotide medications. In addition to enhancing their product offers in antisense oligonucleotides, key companies in Europe are focusing on strategic mergers and acquisitions.

The Antisense Oligonucleotide Therapeutics Market Report Scope

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 13.50 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Billion and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type of Antisense Molecule, ASO Generation, Phase of Development, Lead Candidates, Target Genes, Target Disease Indications, Target Therapeutic Areas, Route of Administration, Type of Therapy

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia

Competitive Landscape

Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Sarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., Enzo Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, GlaxoSmithKline plc, Gerona Corporation, Gradualist, ICO Therapeutics, Aptos Biosciences, Marina Biotech, mirage Therapeutics, Inc., Synodic, Inc., Oncogene Pharmaceuticals Inc., Pharm axis Ltd, Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc., and RI Pharmaceuticals, among others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Antisense Oligonucleotide Therapeutics Market Snapshot

Chapter 4. Global Antisense Oligonucleotide Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: Type of Antisense Molecule Estimates & Trend Analysis
5.1. Type of Antisense Molecule & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Antisense Molecule:

5.2.1. RNA Molecule
5.2.2. DNA Molecule

Chapter 6. Market Segmentation 2: ASO Generation Estimates & Trend Analysis
6.1. ASO Generation & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following ASO Generation:

6.2.1. First-Generation
6.2.2. Second-Generation
6.2.3. Third-Generation
6.2.4. Next-Generation

Chapter 7. Market Segmentation 3: Phase of Development Estimates & Trend Analysis
7.1. Phase of Development & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Phase of Development:

7.2.1. Commercial
7.2.2. Clinical
7.2.3. Preclinical
7.2.4. Discovery Stage

Chapter 8. Market Segmentation 4: Route of Administration Estimates & Trend Analysis
8.1. Route of Administration & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:

8.2.1. Subcutaneous
8.2.2. Intravenous
8.2.3. Intrathecal
8.2.4. Intravitreal
8.2.5. Others

Chapter 9. Market Segmentation 5: Type of Therapy Estimates & Trend Analysis
9.1. Type of Therapy & Market Share, 2023 & 2031
9.1.1. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Therapy:

9.1.2. Monotherapy
9.1.3. Combination Therapy
9.1.4. Both

Chapter 10. Antisense Oligonucleotide Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis

10.1. North America
10.1.1. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Antisense Molecule, 2024-2031
10.1.2. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts ASO Generation, 2024-2031
10.1.3. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Phase of Development, 2024-2031
10.1.4. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2024-2031
10.1.5. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Therapy, 2024-2031
10.1.6. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

10.2. Europe
10.2.1. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Antisense Molecule, 2024-2031
10.2.2. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts ASO Generation, 2024-2031
10.2.3. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Phase of Development, 2024-2031
10.2.4. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2024-2031
10.2.5. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Therapy, 2024-2031
10.2.6. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

10.3. Asia Pacific
10.3.1. Asia Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Antisense Molecule, 2024-2031
10.3.2. Asia Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts ASO Generation, 2024-2031
10.3.3. Asia-Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Phase of Development, 2024-2031
10.3.4. Asia-Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2024-2031
10.3.5. Asia-Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Therapy, 2024-2031
10.3.6. Asia Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

10.4. Latin America
10.4.1. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Antisense Molecule, 2024-2031
10.4.2. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts ASO Generation, 2024-2031
10.4.3. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Phase of Development, 2024-2031
10.4.4. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2024-2031
10.4.5. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Therapy, 2024-2031
10.4.6. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

10.5. Middle East & Africa
10.5.1. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Type of Antisense Molecule, 2024-2031
10.5.2. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts ASO Generation, 2024-2031
10.5.3. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Phase of Development, 2024-2031
10.5.4. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2024-2031
10.5.5. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Type of Therapy, 2024-2031
10.5.6. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles

11.2.1. Sarepta Therapeutics,
11.2.2. Biogen,
11.2.3. Alnylam Pharmaceuticals, Inc
11.2.4. Antisense Therapeutics Limited,
11.2.5. Sarna Therapeutics GmbH,
11.2.6. Arrowhead Pharmaceuticals, Inc.,
11.2.7. Atlantic Pharmaceuticals, Inc.,
11.2.8. Enzo Pharmaceuticals, Inc.,
11.2.9. Bio-Path Holdings, Inc.,
11.2.10. Gene Signal International SA,
11.2.11. GlaxoSmithKline plc,
11.2.12. Gerona Corporation,
11.2.13. Gradualist,
11.2.14. ICO Therapeutics,
11.2.15. Aptos Biosciences,
11.2.16. Marina Biotech,
11.2.17. mirage Therapeutics, Inc.,
11.2.18. Synodic, Inc.,
11.2.19. Oncogene Pharmaceuticals Inc.,
11.2.20. Pharm axis Ltd,
11.2.21. Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc.,
11.2.22. RI Pharmaceuticals,
11.2.23. Ionis Pharmaceuticals
11.2.24. ProQR Therapeutics
11.2.25. Sarepta Therapeutics
11.2.26. Sterna Biologicals
11.2.27. Wave Life Sciences
11.2.28. Endospan
11.2.29. Getinge AB
11.2.30. Boston Scientific Corporation
11.2.31. InspireMD
11.2.32. Japan Lifeline Co., Ltd.
11.2.33. Medtronic

Segmentation of Antisense Oligonucleotide Therapeutics Market-

Antisense Oligonucleotides Market- Type of Antisense Molecule

  • RNA Molecule
  • DNA Molecule

oligonuleotide

Antisense Oligonucleotides Market- ASO Generation

  • First-Generation
  • Second-Generation
  • Third-Generation
  • Next-Generation

Antisense Oligonucleotides Market- Phase of Development

  • Commercial
  • Clinical
  • Preclinical
  • Discovery Stage

Antisense Oligonucleotides Market- Route of Administration

  • Subcutaneous
  • Intravenous
  • Intrathecal
  • Intravitreal
  • Others

Antisense Oligonucleotides Market- Type of Therapy

  • Monotherapy
  • Combination Therapy
  • Both

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the Antisense Oligonucleotide Therapeutics Market Growth?

Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Sarna Therapeutics GmbH, Arrowhead

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach